Medarex may receive future milestone payments and royalties should this product candidate progress to commercialization and achieve commercial sales.
Howard Pien, president and CEO of Medarex, said: “We are excited by this regulatory filing for approval of a fully human antibody developed by Medarex’s technology, and we are pleased by the advancements that Centocor continues to make with these antibodies.”